Searchable abstracts of presentations at key conferences in endocrinology

ea0077p72 | Metabolism, Obesity and Diabetes | SFEBES2021

Impact of PCSK9 Inhibitors on hypercholesterolaemic patients at a tertiary centre lipid clinic

Israni Alisha , Jones Ben , Salem Victoria , Bravis Vassiliki

Background: Elevated low-density lipoprotein cholesterol (LDL-C), which arises due to genetic and environmental factors, has a causal role in the pathogenesis of cardiovascular disease (CVD). Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are approved for patients with familial hypercholesterolaemia (FH) and patients at high risk of CVD due to non-familial hypercholesterolaemia (non-FH). In clinical trials, PCSK9 inhibitors are well-tolerated and lead to redu...

ea0086p14 | Adrenal and Cardiovascular | SFEBES2022

Factors which contribute to LDL-C target attainment in familial hypercholesterolaemia

Vineall Owen , Jones Ben , Cegla Jaimini , David Alessia

Background: In the UK, NICE guidelines for familial hypercholesterolaemia (FH) recommend a greater than 50% reduction in low-density lipoprotein-cholesterol (LDL-C) as the therapeutic target. However, despite the availability of a range of lipid lowering medication, this target is often difficult to achieve and, more importantly, maintain life-long. Understanding factors that affect LDL-C target achievement is key to reducing cardiovascular disease (CVD) risk. Currently, there...

ea0086p163 | Adrenal and Cardiovascular | SFEBES2022

Validating the cholesterol-year-score as a predictor of major cardiovascular events in familial hypercholesterolaemia

Vineall Owen , Jones Ben , David Alessia , Cegla Jaimini

Background: Cardiovascular disease (CVD) risk in familial hypercholesterolaemia (FH) is driven by cumulative exposure to high low-density lipoprotein cholesterol (LDL-C) levels. Previously, LDL-C burden has been loosely approximated using the cholesterol year score (CYS) based on two LDL-C readings only. We aimed to determine whether a more sophisticated LDL-C burden score based on serial LDL-C measurements, could more accurately predict major atherosclerotic cardiovascular ev...

ea0065p206 | Metabolism and Obesity | SFEBES2019

Role of palmitoylation on GLP-1 receptor responses in pancreatic beta cells

Lyu Zekun , Piedade Carolina , Bitsi Stavroula , Jones Ben , Tomas Alejandra

We have previously described how signaling responses for the glucagon-like peptide-1 receptor (GLP-1R), a class B GPCR that plays key roles in metabolic regulation and is a prime type 2 diabetes (T2D) target, are modulated by intracellular membrane trafficking. We have also recently shown that binding to the therapeutic GLP-1R agonist exendin-4 (Exenatide) triggers increased clustering and segregation of biologically active GLP-1Rs into cholesterol-rich plasma membrane nanodom...

ea0091wd4 | Workshop D: Disorders of the adrenal gland | SFEEU2023

Cushing’s syndrome: keep searching, and then search for more!

Kapoor Ashutosh , Singh Ainesh , Vaineri Erika , Agha-Jaffar Rochan , Jones Ben , Cox Jeremy , Wernig Florian , Robinson Stephen , Al-Sahaf May

We present the case of a 53-year-old lady who was recently diagnosed with Type 2 Diabetes, Hypertension and Dyslipidaemia. She was referred by the lipid clinic with a 3-month history of progressive facial swelling, hyperpigmentation and proximal myopathy. Clinical history and examination were highly suspicious of endogenous hypercortisolaemia. An initial overnight dexamethasone suppression test yielded an elevated morning cortisol (752 nmol/l, normal <50nmol/l). Two 24-hou...

ea0065p235 | Metabolism and Obesity | SFEBES2019

Insights into the mechanisms underpinning the physiological effects of biased GLP-1 receptor agonists

Lucey Maria , Pickford Phil , Ma Yue , Shchepinova Maria , Tate Ed , McGinty James , French Paul , Davies Samuel , Xavier Gabriela Da Silva , Stolarczyk Emilie , Minnion James , Rutter Guy , Bloom Steve , Tomas Alejandra , Jones Ben

Glucagon-like peptide-1 receptor (GLP-1R) agonists are effective treatments for type 2 diabetes and obesity. We recently described ‘biased’ peptide GLP-1R agonists modelled on exendin-4 which uncouple the pronounced endocytosis that usually accompanies GLP-1R activation, leading to prolongation of intracellular signalling responses. Here, we show that the metabolic consequences of biased GLP-1R activation in vivo are dominated by improvements in blood glucos...

ea0031oc4.5 | Obesity, metabolism and bone | SFEBES2013

Energy intake following infusion of glucagon and GLP-1: a double-blind crossover study

Cegla Jaimini , Troke Rachel , Jones Ben , Tharakan George , McCullough Katherine , Wilde Julia , Lim Chung Thong , Parvizi Naseem , Hussein Mohamed , Minnion James , Cuenco Joyceline , Chambers Edward , Ghatei Mohammad , Tan Tricia , Bloom Stephen

Obesity is a growing global epidemic and current medical therapies have proven inadequate. Endogenous satiety hormones provide an attractive target for the development of drugs which aim to cause effective weight loss with minimal side effects. Two related peptide hormones, glucagon and glucagon-like peptide 1 (GLP-1), are the subject of this investigation. Both have been found to reduce appetite and cause weight loss. Additionally, glucagon increases energy expenditure. It is...